Kane Biotech Inc. (KNE.V)
CAD 0.08
(-6.25%)
CAD 0.08
(-6.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 148.98 Thousand CAD | -94.42% |
| 2022 | 2.66 Million CAD | 65.97% |
| 2021 | 1.6 Million CAD | 19.84% |
| 2020 | 1.34 Million CAD | -20.78% |
| 2019 | 1.69 Million CAD | 234.51% |
| 2018 | 506.27 Thousand CAD | -51.1% |
| 2017 | 1.03 Million CAD | 322.99% |
| 2016 | 244.75 Thousand CAD | 133.94% |
| 2015 | 104.62 Thousand CAD | 149.71% |
| 2014 | 41.89 Thousand CAD | -73.8% |
| 2013 | 159.94 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | -100.0% |
| 2007 | 17.15 Thousand CAD | -28.81% |
| 2006 | 24.09 Thousand CAD | 0.0% |
| 2005 | - CAD | -100.0% |
| 2004 | 13.41 Thousand CAD | -82.5% |
| 2003 | 76.64 Thousand CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 51.88 Thousand CAD | 108.2% |
| 2024 Q2 | 620.43 Thousand CAD | 1095.77% |
| 2023 FY | 148.98 Thousand CAD | -94.42% |
| 2023 Q1 | 677.61 Thousand CAD | -2.03% |
| 2023 Q2 | 657.31 Thousand CAD | -3.0% |
| 2023 Q4 | -633.06 Thousand CAD | -188.19% |
| 2023 Q3 | 717.85 Thousand CAD | 9.21% |
| 2022 Q3 | 571.68 Thousand CAD | -31.91% |
| 2022 Q4 | 691.65 Thousand CAD | 20.98% |
| 2022 Q2 | 839.57 Thousand CAD | 48.48% |
| 2022 Q1 | 565.43 Thousand CAD | 37.34% |
| 2022 FY | 2.66 Million CAD | 65.97% |
| 2021 Q1 | 376.03 Thousand CAD | 46.13% |
| 2021 Q3 | 541.3 Thousand CAD | 94.2% |
| 2021 Q4 | 411.69 Thousand CAD | -23.94% |
| 2021 Q2 | 278.74 Thousand CAD | -25.87% |
| 2021 FY | 1.6 Million CAD | 19.84% |
| 2020 Q2 | 267.49 Thousand CAD | -41.36% |
| 2020 Q4 | 257.33 Thousand CAD | -28.64% |
| 2020 Q3 | 360.6 Thousand CAD | 34.81% |
| 2020 Q1 | 456.13 Thousand CAD | -19.14% |
| 2020 FY | 1.34 Million CAD | -20.78% |
| 2019 Q2 | 221.29 Thousand CAD | -64.38% |
| 2019 Q3 | 286.83 Thousand CAD | 29.62% |
| 2019 Q4 | 564.13 Thousand CAD | 96.68% |
| 2019 FY | 1.69 Million CAD | 234.51% |
| 2019 Q1 | 621.25 Thousand CAD | 199.0% |
| 2018 Q4 | 207.77 Thousand CAD | 89.25% |
| 2018 Q1 | 93.21 Thousand CAD | -87.77% |
| 2018 Q2 | 95.81 Thousand CAD | 2.79% |
| 2018 FY | 506.27 Thousand CAD | -51.1% |
| 2018 Q3 | 109.79 Thousand CAD | 14.59% |
| 2017 Q4 | 762.22 Thousand CAD | 1255.14% |
| 2017 FY | 1.03 Million CAD | 322.99% |
| 2017 Q3 | 56.24 Thousand CAD | -45.21% |
| 2017 Q1 | 114.17 Thousand CAD | 53.01% |
| 2017 Q2 | 102.65 Thousand CAD | -10.09% |
| 2016 FY | 244.75 Thousand CAD | 133.94% |
| 2016 Q4 | 74.61 Thousand CAD | 25.88% |
| 2016 Q2 | 73.84 Thousand CAD | 99.48% |
| 2016 Q3 | 59.27 Thousand CAD | -19.72% |
| 2016 Q1 | 37.01 Thousand CAD | 61.84% |
| 2015 Q2 | 37.67 Thousand CAD | 15.67% |
| 2015 Q4 | 22.87 Thousand CAD | 98.7% |
| 2015 FY | 104.62 Thousand CAD | 149.71% |
| 2015 Q3 | 11.51 Thousand CAD | -69.44% |
| 2015 Q1 | 32.56 Thousand CAD | 40.05% |
| 2014 Q4 | 23.25 Thousand CAD | 24.73% |
| 2014 Q1 | - CAD | -100.0% |
| 2014 Q3 | 18.64 Thousand CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | 41.89 Thousand CAD | -73.8% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | 159.94 Thousand CAD | 0.0% |
| 2013 Q4 | 159.94 Thousand CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q1 | - CAD | 100.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 Q1 | - CAD | -100.0% |
| 2008 FY | - CAD | -100.0% |
| 2008 Q4 | -22.4 Thousand CAD | -430.5% |
| 2008 Q3 | 6780.00 CAD | -36.69% |
| 2008 Q2 | 10.71 Thousand CAD | 0.0% |
| 2007 Q1 | 5775.00 CAD | -30.7% |
| 2007 Q2 | 3514.00 CAD | -39.15% |
| 2007 FY | 17.15 Thousand CAD | -28.81% |
| 2007 Q3 | 3637.00 CAD | 3.5% |
| 2007 Q4 | 4230.00 CAD | 16.3% |
| 2006 Q2 | 2346.00 CAD | 0.0% |
| 2006 FY | 24.09 Thousand CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q4 | 8333.00 CAD | -20.62% |
| 2006 Q3 | 10.49 Thousand CAD | 347.49% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 Q1 | 8873.00 CAD | 137.76% |
| 2005 Q2 | - CAD | -100.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2005 FY | - CAD | -100.0% |
| 2004 Q4 | -23.5 Thousand CAD | -292.8% |
| 2004 Q3 | 12.18 Thousand CAD | 129.29% |
| 2004 Q2 | 5316.00 CAD | -40.28% |
| 2004 FY | 13.41 Thousand CAD | -82.5% |
| 2004 Q1 | 8902.00 CAD | -16.79% |
| 2003 Q2 | 4694.00 CAD | 0.0% |
| 2003 Q3 | 14.38 Thousand CAD | 206.43% |
| 2003 FY | 76.64 Thousand CAD | 0.0% |
| 2003 Q4 | 10.69 Thousand CAD | -25.63% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.98 Million CAD | 92.49% |
| Covalon Technologies Ltd. | 26.59 Million CAD | 99.44% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | 1.07 Million CAD | 86.087% |
| MedMira Inc. | 432.52 Thousand CAD | 65.556% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |